Volume 8, Issue 1, Pages (July 2003)

Slides:



Advertisements
Similar presentations
Christina K. Marko, Balaraj B. Menon, Gang Chen, Jeffrey A
Advertisements

Bmi-1 Is Essential for the Tumorigenicity of Neuroblastoma Cells
Molecular Therapy - Nucleic Acids
Matrix Metalloproteinase-9–Null Mice Are Resistant to TGF-β–Induced Anterior Subcapsular Cataract Formation  Anna Korol, Giuseppe Pino, Dhruva Dwivedi,
Figure 2. Macrophages in dystrophic muscle in vivo and in vitro express Klotho. (A) A cross-section of 4-week-old mdx muscle labeled with antibodies to.
Volume 22, Issue 11, Pages (November 2014)
Volume 2, Issue 1, Pages (July 2000)
Reduced hind limb ischemia-reperfusion injury in Toll-like receptor-4 mutant mice is associated with decreased neutrophil extracellular traps  Rahmi Oklu,
Volume 6, Issue 5, Pages (November 2002)
Effects of N-acetylcysteine on skeletal muscle structure and function in a mouse model of peripheral arterial insufficiency  Bruno T. Roseguini, PhD,
Volume 11, Issue 1, Pages (January 2005)
Volume 14, Issue 1, Pages (July 2006)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 17, Issue 5, Pages (May 2009)
Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model  Karima Relizani, Graziella Griffith,
Prmt7 deficiency causes a fiber-type switch toward glycolytic.
Volume 10, Issue 6, Pages (June 2018)
Transgene Expression in the Brain Stem Effected by Intramuscular Injection of Polyethylenimine/DNA Complexes  Shu Wang, Nan Ma, Shujun J. Gao, Hanry Yu,
Molecular Therapy - Nucleic Acids
Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Jason.
Volume 22, Issue 7, Pages (July 2014)
Molecular Therapy - Methods & Clinical Development
The extent of degeneration of cruciate ligament is associated with chondrogenic differentiation in patients with osteoarthritis of the knee  K. Kumagai,
Volume 10, Issue 5, Pages (November 2004)
Volume 2, Issue 1, Pages (July 2000)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 6, Pages (June 2017)
Molecular Therapy - Nucleic Acids
Volume 90, Issue 4, Pages (August 1997)
Volume 90, Issue 4, Pages (August 1997)
Molecular Therapy - Nucleic Acids
Volume 10, Issue 2, Pages (February 2018)
Volume 18, Issue 12, Pages (December 2010)
Molecular Therapy - Nucleic Acids
Volume 11, Issue 3, Pages (September 2006)
Volume 143, Issue 1, Pages (October 2010)
Development of Novel Micro-dystrophins with Enhanced Functionality
Volume 6, Issue 3, Pages (September 2007)
Volume 25, Issue 10, Pages (October 2017)
Melissa L. Ehlers, Barbara Celona, Brian L. Black  Cell Reports 
Volume 18, Issue 1, Pages (January 2010)
Volume 16, Issue 5, Pages (August 2016)
The pathological role of Bax in cisplatin nephrotoxicity
Volume 12, Issue 4, Pages (October 2005)
Volume 16, Issue 4, Pages (April 2008)
Increased Expression of Wnt2 and SFRP4 in Tsk Mouse Skin: Role of Wnt Signaling in Altered Dermal Fibrillin Deposition and Systemic Sclerosis  Julie Bayle,
Volume 82, Issue 3, Pages (August 2012)
Molecular Therapy - Nucleic Acids
Conditional Loss of Pten in Myogenic Progenitors Leads to Postnatal Skeletal Muscle Hypertrophy but Age-Dependent Exhaustion of Satellite Cells  Feng.
Volume 17, Issue 2, Pages (October 2016)
Volume 10, Issue 2, Pages (August 2009)
Volume 25, Issue 4, Pages (April 2017)
Volume 10, Issue 4, Pages (October 2004)
Volume 25, Issue 11, Pages (November 2017)
by Christopher E. Nelson, Chady H. Hakim, David G
Volume 26, Issue 10, Pages (October 2018)
Volume 23, Issue 8, Pages (August 2015)
Link between MHC Fiber Type and Restoration of Dystrophin Expression and Key Components of the DAPC by Tricyclo-DNA-Mediated Exon Skipping  Saleh Omairi,
Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy  Pam M Van Ry, Ryan D.
Quan Jin, Chunping Qiao, Jianbin Li, Juan Li, Xiao Xiao 
Richard J. Sanders, MD 1, William H. Pearce, MD 2 
Volume 23, Issue 7, Pages (July 2015)
Volume 17, Issue 5, Pages (May 2009)
Gang Han, Caorui Lin, Hanhan Ning, Xianjun Gao, HaiFang Yin 
Volume 10, Issue 5, Pages (November 2004)
Fig. 4. HERV-K env expression and injury to lower motor neurons.
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
Fig. 4 Systemic AAV9 delivery of gene editing components to ΔEx44 mice rescues dystrophin expression. Systemic AAV9 delivery of gene editing components.
Aminoglycoside Enhances the Delivery of Antisense Morpholino Oligonucleotides In Vitro and in mdx Mice  Mingxing Wang, Bo Wu, Sapana N. Shah, Peijuan.
Presentation transcript:

Volume 8, Issue 1, Pages 80-89 (July 2003) Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice  Patrick Dunant, Nancy Larochelle, Christian Thirion, Rolf Stucka, Daniel Ursu, Basil J Petrof, Eckhard Wolf, Hanns Lochmüller  Molecular Therapy  Volume 8, Issue 1, Pages 80-89 (July 2003) DOI: 10.1016/S1525-0016(03)00129-1 Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Immunoblot analysis of full-length (427 kDa) and minidystrophin (220 kDa) in various muscles and other tissues of wild-type (wt; C57BL/6) and transgenic (tg) mice. Muscle samples show a prominent band (myosin at 200 kDa) on the posttransfer Coomassie gel (loading control). Dystrophin expression in transgenic mice is muscle-specific. It is strong in fast-twitch muscles but weak or absent in slow-twitch muscles, diaphragm, and heart. Molecular Therapy 2003 8, 80-89DOI: (10.1016/S1525-0016(03)00129-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Immunofluorescent localization of dystrophin in muscles from control and transgenic mice. TA (A, E, I, M, Q), EDL (B, F, J, N, R), M. soleus (C, G, K, O, S), and diaphragm (D, H, L, P, T). (A–P) Mice at the age of 7 months and (Q–T) mice at the age of 20 months are represented. Note the regularity of dystrophin expression in C57BL/6 mice (A–D), its absence in mdx mice (E–H), and the mosaic pattern in adult muscle from both transgenic lines, line 2 (I–L) and line 1 (N–P), at the age of 7 months, and line 2 at the age of 20 months (Q–T). Scale bar, 50 μm. Molecular Therapy 2003 8, 80-89DOI: (10.1016/S1525-0016(03)00129-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Correlation of dystrophin expression, central nucleation, and metabolic fiber type. Sections from 7-month-old C57BL/6 TA (A), mdx TA (B), transgenic TA (C), and transgenic EDL (D). Dystrophin immunostaining (red), nuclear bisbenzimide staining (blue), NADH-tetrazolium reductase (glycolytic fibers light, oxidative fibers dark). In transgenic muscles, dystrophin-positive fibers are large; central nuclei are nearly absent (C, D). In contrast, dystrophin-negative fibers are smaller, are mostly oxidative, and often have central nuclei (C, D). Note the central nucleus in the revertant (dystrophin-positive) fiber in the mdx muscle (B). Scale bar, 50 μm. Molecular Therapy 2003 8, 80-89DOI: (10.1016/S1525-0016(03)00129-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 4 Mechanics of isolated EDL muscle. Evaluation of specific twitch force (A), specific tetanic force (B), and resistance to eccentric contractions (C) for female wild-type (black), transgenic (gray), and mdx (white) mice. Between 5 and 18 muscles were analyzed in every group. Data are presented as means ± SEM. Statistically relevant differences between transgenic and mdx mice are indicated (*P < 0.05; **P < 0.01). Differences between wild-type and mdx mice are highly significant for eccentric contraction (P < 0.001; not indicated). Molecular Therapy 2003 8, 80-89DOI: (10.1016/S1525-0016(03)00129-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions